Article Text

Download PDFPDF
Division and discord in the Clinical Trials Regulation
  1. David Shaw1,2,
  2. David Townend1
  1. 1Department of Health, Ethics and Society, CAPHRI Research School, Maastricht University, Maastricht, the Netherlands
  2. 2Institute for Biomedical Ethics, University of Basel, Basel, Switzerland
  1. Correspondence to Dr David Shaw, Department of Health, Ethics and Society, Maastricht University, Maastricht, 6200 MD, the Netherlands; Postbus 616;{at}


The Clinical Trials Regulation is intended to harmonise and streamline the review and conduct of clinical trials in the European Union. In this paper, we identify and analyse several serious issues concerning the division imposed by the Regulation between scientific review and ethical review. We conclude that these problems may compromise the objectives of the Regulation.

  • Clinical trials
  • Ethics Committees/Consultation
  • Policy Guidelines/Inst. Review Boards/Review Cttes.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Correction notice This article has been corrected since it first published Online First. The title has been amended.

  • Contributors DS and DT conceived the article together and DS wrote the first draft. Both authors revised the intellectual content.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.